From this summers conference online, whilst its a small group of patients the results for MCL patients are promising and shows a bigger trial is needed to see if these results can be repeated.
link here
Mantle Cell Lymphoma (MCL)
Ibrutinib plus venetoclax in combination with obinutuzumab was evaluated in patients with newly diagnosed MCL by Le Gouill and colleagues in a phase I/II trial to potentially bypass mechanisms of resistance. Here, findings suggest synergistic mechanisms contribute to very high CR rates early in the treatment duration (CR by cycle 6 was 86%; PR was 7%) with an ORR of 93%. All 12 evaluable patients achieved uMRD by cycle 3. Treatment was well tolerated without any relevant clinical manifestations. The results of this study are overwhelmingly positive, with a 2-year OS rate of 100%, warranting the need for larger clinical trials and supporting the potential use of this regimen as a first-line treatment option in patients with newly diagnosed MCL.
